| Dorothy A Penaloza, MD | |
|
3333 Riverbend Drive, Springfield, OR 97477-8800 | |
| (541) 222-3154 | |
| (541) 222-3359 |
| Full Name | Dorothy A Penaloza |
|---|---|
| Gender | Female |
| Speciality | Anesthesiology |
| Experience | 20 Years |
| Location | 3333 Riverbend Drive, Springfield, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093859647 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD28095 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mckenzie-willamette Medical Center | Springfield, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Northwest Anesthesia Physicians Pc | 3274420138 | 76 |
News Archive
CardioInsight Technologies, Inc., a leading developer of non-invasive electrocardiographic mapping technology, announced today that it has completed a long-term strategic financing that provides the Company with an initial investment of $15 million.
When the National Institute of Standards and Technology issued the world's first standardized monoclonal antibody in July 2016, the exhaustively analyzed protein known as NISTmAb was intended as a valuable tool for biopharmaceutical companies.
Debates about legalizing marijuana have focused on crime rates, economic benefits, and health effects among adults. But a study published today from researchers at Nationwide Children's Hospital shows that the risk to young children of swallowing, breathing in or otherwise being exposed to marijuana also needs to be considered.
Bioaxial, developers of super-resolved fluorescence microscopy for the extended imaging of live cells, today announces the completion of a EUR 1.9 million (USD 2.7 million) equity investment by three new large investors; Amorcage Technologique Investissement (a fund managed by CEA Investissement), Inserm Transfert Initiative and Viveris Management plus a range of individual investors.
"We know from previous studies that patients with symptomatic mitral regurgitation are at increased risk of death, but for those without symptoms the picture has been murkier," says Maurice Enriquez-Sarano, M.D., the Mayo Clinic cardiologist who led the study. "In this study we followed a large population of asymptomatic patients prospectively to identify keys to improved long-term outcomes, and to determine when patients should consider surgery."
› Verified 5 days ago
| Entity Name | Northwest Anesthesia Physicians Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770531196 PECOS PAC ID: 3274420138 Enrollment ID: O20040304000014 |
News Archive
CardioInsight Technologies, Inc., a leading developer of non-invasive electrocardiographic mapping technology, announced today that it has completed a long-term strategic financing that provides the Company with an initial investment of $15 million.
When the National Institute of Standards and Technology issued the world's first standardized monoclonal antibody in July 2016, the exhaustively analyzed protein known as NISTmAb was intended as a valuable tool for biopharmaceutical companies.
Debates about legalizing marijuana have focused on crime rates, economic benefits, and health effects among adults. But a study published today from researchers at Nationwide Children's Hospital shows that the risk to young children of swallowing, breathing in or otherwise being exposed to marijuana also needs to be considered.
Bioaxial, developers of super-resolved fluorescence microscopy for the extended imaging of live cells, today announces the completion of a EUR 1.9 million (USD 2.7 million) equity investment by three new large investors; Amorcage Technologique Investissement (a fund managed by CEA Investissement), Inserm Transfert Initiative and Viveris Management plus a range of individual investors.
"We know from previous studies that patients with symptomatic mitral regurgitation are at increased risk of death, but for those without symptoms the picture has been murkier," says Maurice Enriquez-Sarano, M.D., the Mayo Clinic cardiologist who led the study. "In this study we followed a large population of asymptomatic patients prospectively to identify keys to improved long-term outcomes, and to determine when patients should consider surgery."
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dorothy A Penaloza, MD P.o. Box 7247, Springfield, OR 97475-0011 Ph: (541) 686-9551 | Dorothy A Penaloza, MD 3333 Riverbend Drive, Springfield, OR 97477-8800 Ph: (541) 222-3154 |
News Archive
CardioInsight Technologies, Inc., a leading developer of non-invasive electrocardiographic mapping technology, announced today that it has completed a long-term strategic financing that provides the Company with an initial investment of $15 million.
When the National Institute of Standards and Technology issued the world's first standardized monoclonal antibody in July 2016, the exhaustively analyzed protein known as NISTmAb was intended as a valuable tool for biopharmaceutical companies.
Debates about legalizing marijuana have focused on crime rates, economic benefits, and health effects among adults. But a study published today from researchers at Nationwide Children's Hospital shows that the risk to young children of swallowing, breathing in or otherwise being exposed to marijuana also needs to be considered.
Bioaxial, developers of super-resolved fluorescence microscopy for the extended imaging of live cells, today announces the completion of a EUR 1.9 million (USD 2.7 million) equity investment by three new large investors; Amorcage Technologique Investissement (a fund managed by CEA Investissement), Inserm Transfert Initiative and Viveris Management plus a range of individual investors.
"We know from previous studies that patients with symptomatic mitral regurgitation are at increased risk of death, but for those without symptoms the picture has been murkier," says Maurice Enriquez-Sarano, M.D., the Mayo Clinic cardiologist who led the study. "In this study we followed a large population of asymptomatic patients prospectively to identify keys to improved long-term outcomes, and to determine when patients should consider surgery."
› Verified 5 days ago
Albert R Cho, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3333 Riverbend Dr, Springfield, OR 97477 Phone: 541-686-7300 | |
Mark N Bodily, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 3333 Riverbend Dr, Springfield, OR 97477 Phone: 541-222-3154 | |
Ximeng Yang, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3333 Riverbend Dr, Springfield, OR 97477 Phone: 541-222-3154 Fax: 541-222-3359 | |
Daniel R Hagengruber, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3333 Riverbend Dr, Springfield, OR 97477 Phone: 541-222-3154 | |
Brian P Jones, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3333 Riverbend Dr, Springfield, OR 97477 Phone: 541-222-3154 | |
Christopher B Hagen, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 3333 Riverbend Drive, Springfield, OR 97477 Phone: 541-222-3154 Fax: 541-222-3359 |